Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
dalazatide · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| 30ug dalazatide | EXPERIMENTAL | 12 subjects, 10 given active agent and 2 given placebo by subcutaneous injection twice weekly for 4 weeks. |
| 60ug dalazatide | EXPERIMENTAL | 12 subjects, 10 given active agent and 2 given placebo by subcutaneous injection twice weekly for 4 weeks. |
| dalazatide 5ug | EXPERIMENTAL | 8 subjects, 6 given active agent and 2 given placebo |
| dalazatide 15ug | EXPERIMENTAL | 8 subjects, 6 given active agent and 2 given placebo |
| dalazatide 30ug | EXPERIMENTAL | 8 subjects, 6 given active agent and 2 given placebo |
| dalazatide 60ug | EXPERIMENTAL | 8 subjects, 6 given active agent and 2 given placebo |
| Name | Type | Description |
|---|---|---|
| dalazatide | DRUG | Subcutaneous injection twice per week for a total of 9 doses, followed by four weeks of follow-up. |
| placebo | DRUG | placebo, Subcutaneous injection twice per week for a total of 9 doses |
Inclusion Criteria: 1. Adult male and female subjects, ages 18-65; 2. Active plaque psoriasis with ≥3% BSA involved; 3. An adequate number of vulgar psoriatic plaques of at least 2 cm X 2 cm with Target Lesion Investigator Global Assessment scores \>3, that are not located on the face, scalp, groin...
Dalazatide is an investigational small molecule being studied for plaque psoriasis and in healthy volunteers. It is developed by TuHURA Biosciences, Inc. (HURA). Dalazatide is in Phase 1 clinical development and is not approved by the FDA.
Dalazatide is a small molecule that targets the Kv1.3 potassium channel on effector memory T cells. By blocking this channel, it may modulate the immune response involved in plaque psoriasis. This mechanism is being evaluated in early-stage clinical trials.
Dalazatide is being developed by TuHURA Biosciences, Inc., a biopharmaceutical company listed on the stock exchange under the ticker HURA. The company is conducting Phase 1 clinical trials to evaluate the safety and pharmacodynamics of dalazatide.
Dalazatide is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. Two Phase 1 trials have been completed, one in patients with plaque psoriasis and one in healthy volunteers.
Dalazatide has been studied in two completed Phase 1 trials. NCT02435342 evaluated a 4-week course in patients with active plaque psoriasis in Canada. NCT02446340 was a multiple ascending dose study in healthy volunteers in the United States. Both trials are completed.
Yes, dalazatide is also known as ShK-186. Clinical trial records refer to the drug as ShK-186 (Dalazatide). Both names refer to the same investigational small molecule being developed by TuHURA Biosciences for plaque psoriasis.